This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
Annexin Pharmaceuticals is a Swedish privately held biotech company [1] [2] developing new therapeutic approaches for inflammatory cardiovascular diseases. The concept for the therapy is based on the anti-inflammatory properties of Annexin A5, a body own protective protein that acts simultaneously against several key pathogenic mechanisms of cardiovascular diseases. The company is currently focusing on treatment of peripheral artery disease (PAD).